source
- Capricor shareholders face board overhaul push as investors demand meeting and capital-preservation plan amid DMD cell therapy delayKaos Capital, describing itself as a significant shareholder of Capricor Therapeutics, sent a letter to fellow investors calling for an immediate meeting, a change of the board, and a capital-prese…
- Spruce Biosciences appoints former Zevra Therapeutics CMO Adrian QuartelSpruce Biosciences announced the hiring of Adrian Quartel as its new chief medical officer. Quartel joins Spruce after serving as CMO at Zevra Therapeutics, where he oversaw clinical development.…